PMCB (PharmaCyte Biotech) Cyclically Adjusted Book per Share: $8.07 (As of Jan. 2026)


PMCB PharmaCyte Biotech Inc PMCB
32 GF Score
Price $0.75
! 2 Warning Signs
View Full Analysis

What is PharmaCyte Biotech Cyclically Adjusted Book per Share?

PharmaCyte Biotech PMCB +1.44% 32 Cyclically Adjusted Book per Share is $8.07 as of Jan. 2026. GuruFocus rates PMCB with a GF Score™ of 32/100. The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

PharmaCyte Biotech's adjusted book value per share for the three months ended in Jan. 2026 was $3.589. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $8.07 for the trailing ten years ended in Jan. 2026.

During the past 12 months, PharmaCyte Biotech's average Cyclically Adjusted Book Growth Rate was -12.40% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -0.10% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 15.00% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -2.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of PharmaCyte Biotech was 34.30% per year. The lowest was -30.40% per year. And the median was 6.95% per year.

As of today (2026-06-28), PharmaCyte Biotech's current stock price is $0.7549. PharmaCyte Biotech's Cyclically Adjusted Book per Share for the quarter that ended in Jan. 2026 was $8.07. PharmaCyte Biotech's Cyclically Adjusted PB Ratio of today is 0.09.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of PharmaCyte Biotech was 0.09. The lowest was 0.00. And the median was 0.00.


PharmaCyte Biotech  (NAS:PMCB) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

PharmaCyte Biotech's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=0.7549/8.07
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of PharmaCyte Biotech was 0.09. The lowest was 0.00. And the median was 0.00.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


PharmaCyte Biotech Cyclically Adjusted Book per Share Related Terms


PharmaCyte Biotech Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for PharmaCyte Biotech's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaCyte Biotech Cyclically Adjusted Book per Share Chart

PharmaCyte Biotech Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.63 8.99 10.87 10.08 8.95

PharmaCyte Biotech Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.21 8.95 8.70 8.43 8.07

PMCB vs IMNN, ACXP, ENVB: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, PharmaCyte Biotech's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmaCyte Biotech Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmaCyte Biotech's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where PharmaCyte Biotech's Cyclically Adjusted PB Ratio falls into.


PMCB
32GF Score
PharmaCyte Biotech Inc PMCB
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PharmaCyte Biotech Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, PharmaCyte Biotech's adjusted Book Value per Share data for the three months ended in Jan. 2026 was:

Adj_Book= Book Value per Share /CPI of Jan. 2026 (Change)*Current CPI (Jan. 2026)
=3.589/325.2520*325.2520
=3.589

Current CPI (Jan. 2026) = 325.2520.

PharmaCyte Biotech Quarterly Data

Book Value per Share CPI Adj_Book
201604 12.520 239.261 17.020
201607 12.486 240.628 16.877
201610 11.101 241.729 14.937
201701 12.091 242.839 16.194
201704 13.389 244.524 17.809
201707 13.342 244.786 17.728
201710 11.322 246.663 14.929
201801 8.927 247.867 11.714
201804 8.534 250.546 11.079
201807 8.608 252.006 11.110
201810 7.495 252.885 9.640
201901 7.136 251.712 9.221
201904 6.372 255.548 8.110
201907 5.958 256.571 7.553
201910 5.106 257.346 6.453
202001 4.532 257.971 5.714
202004 4.656 256.389 5.907
202007 4.992 259.101 6.267
202010 5.316 260.388 6.640
202101 4.874 261.582 6.060
202104 4.201 267.054 5.117
202107 3.543 273.003 4.221
202110 4.447 276.589 5.229
202201 4.408 281.148 5.099
202204 4.340 289.109 4.883
202207 4.159 296.276 4.566
202210 4.150 298.012 4.529
202301 4.235 299.170 4.604
202304 4.328 303.363 4.640
202307 4.868 305.691 5.180
202310 4.226 307.671 4.467
202401 3.682 308.417 3.883
202404 3.440 313.548 3.568
202407 6.182 314.540 6.393
202410 6.177 315.664 6.365
202501 5.829 317.671 5.968
202504 7.636 320.795 7.742
202507 6.414 323.048 6.458
202510 5.246 0.000
202601 3.589 325.252 3.589

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $8.07 mean?
PharmaCyte Biotech (PMCB) has a Cyclically Adjusted Book per Share of $8.07 as of Jan. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on PharmaCyte Biotech and its competitors.
Is PharmaCyte Biotech's Cyclically Adjusted Book per Share too high?
PharmaCyte Biotech's current Cyclically Adjusted Book per Share is $8.07. Overall, PharmaCyte Biotech has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does PharmaCyte Biotech's Cyclically Adjusted Book per Share compare to IMNN and ACXP?
PharmaCyte Biotech's Cyclically Adjusted Book per Share of $8.07 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on PharmaCyte Biotech and its competitors. PharmaCyte Biotech's current Cyclically Adjusted Book per Share is $8.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCyte Biotech stock overvalued right now?
PharmaCyte Biotech (PMCB) has a current Cyclically Adjusted Book per Share of $8.07. The current Cyclically Adjusted Book per Share is $8.07. PharmaCyte Biotech's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For PharmaCyte Biotech (PMCB), the current Cyclically Adjusted Book per Share is $8.07 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PharmaCyte Biotech Business Description

Address 3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV, USA, 89169
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
32GF Score

Get the complete analysis for PMCB

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.75
Price